

Irritable Bowel Syndrome (IBS) Treatment Market Competition Analysis 2025: How Players Are Shaping Growth

*The Business Research Company's
Irritable Bowel Syndrome (IBS) Treatment
Global Market Report 2025 – Market Size,
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, December 4, 2025

/EINPresswire.com/ -- "The [Irritable Bowel Syndrome \(IBS\) Treatment market](#) is dominated by a mix of

pharmaceutical leaders and emerging biotechnology innovators. Companies are focusing on advanced therapeutic

formulations, personalized medicine approaches, and gut microbiome-targeted treatments to enhance patient outcomes and expand their market presence. Understanding the competitive landscape is crucial for stakeholders aiming to capitalize on evolving treatment paradigms, strategic partnership.


Which Market Player Is Leading the Irritable Bowel Syndrome (IBS) Treatment Market?

According to our research, AbbVie Inc. led global sales in 2024 with a 15% market share. The gastroenterology division of the company completely involved in irritable bowel syndrome (IBS) treatment market, provides the Treatments for conditions like irritable bowel syndrome (IBS) and chronic idiopathic constipation.

How Concentrated Is the Irritable Bowel Syndrome (IBS) Treatment Market?

The market is concentrated with the top 10 players accounting for 38% of total market revenue in 2024. This level of concentration reflects the dominance of established players leveraging strong brand presence, clinical expertise, and robust distribution networks. Smaller companies focus on innovative therapies and specialized patient needs, highlighting opportunities for differentiation. Going forward, strategic partnerships, mergers, and product innovations are expected to further consolidate market leadership and drive growth.

• Leading companies include:



- o AbbVie Inc. (15%)
- o Bausch Health (5%)
- o Astellas Pharma AS (5%)
- o Ironwood Pharmaceuticals Inc. (5%)
- o Takeda Pharmaceutical Inc. (4%)
- o Ardelyx Inc. (2%)
- o Mallinckrodt Pharmaceuticals plc (1%)
- o Alfasigma (1%)
- o Mahana Therapeutics Inc. (0.1%)
- o Prometheus Laboratories Inc. (0.1%)

Request a free sample of the Irritable Bowel Syndrome (IBS) Treatment Market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=28463&type=smp>

Which Companies Are Leading Across Different Regions?

- North America: Ironwood Pharmaceuticals, Inc., AbbVie Inc., Ardelyx, Inc., Salix Pharmaceuticals, Ltd., Synergy Pharmaceuticals, Inc., CinPhloro Pharma, LLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novartis AG, and Biomerica, Inc. are some of the leading companies in this region.
- Asia Pacific: AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma India Private Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals plc, Merck KGaA, Zydus Lifesciences Limited, Eisai Co., Ltd., Ardelyx, Inc., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., and Astellas Pharma Inc. are some of the leading companies in this region.
- Western Europe: EnteroBiotix Limited, AstraZeneca plc, Takeda Pharmaceutical Company Limited, and Biocodex S.A. are some of the leading companies in this region.
- Eastern Europe: Bayer AG, Ardelyx, Inc., Ironwood Pharmaceuticals, Inc., GlaxoSmithKline plc, Salix Pharmaceuticals, Ltd., and Astellas Pharma Inc. are some of the leading companies in this region.
- South America: Ironwood Pharmaceuticals, Inc., Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Abbott Laboratories, and Novartis AG. are some of the leading companies in this region.

What Are the [Major Competitive Trends in the Market?](#)

- Microbiome-targeted oral therapies are transforming next generation full spectrum microbiome drug designed.
- Example: EnteroBiotix IBS Symptom Severity Scale (March 2025) assigns unique showing clinically meaningful improvements across multiple symptom domains in IBS-C patients
- These innovations offers microbiome modulation with oral dosing and favorable tolerability

Which Strategies Are Companies Adopting to Stay Ahead?

- Launching new products and solutions to strengthen market position
- Forming strategic partnerships and licensing agreements with biotechnology firms, research

organizations

- Focusing on clinical research and innovation to develop next-generation therapies
- Leveraging digital health platforms and patient engagement tools for remote symptom monitoring

Access the detailed Irritable Bowel Syndrome (IBS) Treatment Market report here:

<https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report>

[Learn More About The Business Research Company](#)

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)
[Facebook](#)
[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/872168889>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.